Ad hoc releases are announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
View Featured news and Pulse updates.
Header
Newsroom
Showing 1966 results
October 2026
-
Press release
Novartis remibrutinib delivered comprehensive disease control in Phase III RMS trials, with proven, robust safety profile
Remibrutinib achieved significant and clinically meaningful reduction in relapses vs. teriflunomide, to approximately 1 relapse every 13 years, without the need for chronic B-cell depletion¹˒²MRI… -
Press release
Kisqali® shows clinically meaningful overall survival in broadest HR+/HER2- early breast cancer population at high risk of recurrence
Six-year NATALEE analysis showed ~20% reduction in risk of death compared to ET alone1 Benefit increased over time in invasive disease-free survival and across key secondary endpoints1-3 Patients off… -
Press release
Novartis receives European Commission approval for Cosentyx® in polymyalgia rheumatica (PMR)
Cosentyx® (secukinumab) becomes first and only IL-17A inhibitor approved in Europe for adults with PMR,1 a common inflammatory rheumatic disease with limited advanced treatment options2-6Approval… -
Story People and Culture
Novartis ranks #19 in TIME and Statista’s World’s Best Companies 2026
Novartis has earned a spot among the world’s top performers, ranking #19 in TIME and Statista’s World’s Best Companies 2026 – a significant rise from #114 last year. The recognition reflects progress across three critical areas: business performance, workplace experience, and sustainability.
-
Story Access to Healthcare
Community health takes a village: Screening in the barber’s chair
Novartis is working with community partners to bring heart disease and cancer screening, information and support closer to where people are.
-
Story People and Culture
Novartis achieves Tier 1 in the 2026 CCLA Corporate Mental Health Benchmark
Novartis has reached the highest performance tier in the CCLA Corporate Mental Health Benchmark, recognizing a comprehensive approach to workplace mental health, wellbeing and employee support.
-
Press release
Novartis Rhapsido® (remibrutinib) receives FDA approval as first treatment for symptomatic dermographism (SD), expanding its use beyond chronic spontaneous urticaria (CSU)
In Phase III RemIND trial, twice as many adults taking Rhapsido achieved complete hive resolution by Week 12 vs placebo, with responses seen by Week 21SD is most prevalent type of chronic inducible… -
Press release
Novartis advances multiple sclerosis innovation with late-breaking remibrutinib and broad portfolio data at MSToronto2026
Late-breaking data from positive Phase III REMODEL-1/-2 trials will show efficacy and safety profile of remibrutinib in RMS Novartis to hold virtual investor event highlighting REMODEL data and… -
Story People and Culture
The patient who changed the course of my career
Nazem Atassi, Development Unit Head for Neuroscience and Gene Therapies, Global Drug Development.
September 2026
-
Story Access to Healthcare
Community health takes a village: from Pulpit to Pew
Millions of people around the world continue to face barriers to prevention, diagnosis and treatment for chronic diseases such as heart disease and cancer. To help address these gaps, Novartis is scaling its community health programs from 11 to more than 30 countries by 2030, working alongside local partners to connect more people to care.
-
Story Access to Healthcare
Fortune includes Novartis in 2026 Change The World List for malaria program
For more than three decades, Novartis has been committed to the fight against malaria, one of the world's deadliest diseases. Fortune has now recognized that work by naming our malaria program to its 2026 Change The World list.
-
Story People and Culture
The Day AI Made Me Rethink What Science Could Do
Christian Diehl, Chief Data & Digital Officer, Novartis Biomedical Research